Target intelligence / Profile preview

DPYD antisense RNA 2 (non-protein coding) (DPYD-AS2)

Target
DPYD-AS2
Molecular classification
Long non-coding RNA (lncRNA), Natural antisense transcript (NAT), Other (non-protein coding RNA, gene regulatory RNA)
01

Overview

DPYD antisense RNA 2 (DPYD-AS2) is a long non-coding, natural antisense RNA gene located in the DPYD genomic locus. It is processed in two or three transcript variants on the forward DNA strand and does not encode a protein. DPYD-AS2 is part of a complex regulatory RNA network that modulates DPYD gene expression at the transcriptional and possibly post-transcriptional level. The DPYD gene encodes dihydropyrimidine dehydrogenase, a key enzyme for pyrimidine and chemotherapeutic drug metabolism. Disorders in DPYD regulation—potentially mediated by antisense RNAs like DPYD-AS2—can contribute to disease phenotypes such as enzyme deficiency and severe adverse drug reactions to fluoropyrimidines. While antisense RNAs in general are being investigated as cancer therapy targets, DPYD-AS2 itself is not yet a therapeutic target but represents a candidate for research into regulatory mechanisms and disease-modifying effects.

Other names
DPYD antisense RNA 2DPYD-AS2DPYD antisense RNA 2 (non-protein coding)
02

Mechanism of action

Antisense RNA-mediated regulation of DPYD gene expression, possibly affecting enzyme levels and drug metabolism

03

Biological functions

Regulation of DPYD gene expressionEpigenetic regulationTranscriptional modulation (cis- and trans-acting effects)Potential role in alternative splicing, chromatin organization, and post-transcriptional regulation
04

Disease associations

Potential role in dihydropyrimidine dehydrogenase deficiency (by modulating DPYD activity)Possible indirect roles in cancer and drug toxicity (via regulation of DPYD and fluoropyrimidine metabolism)Other (regulatory RNA implicated in disease susceptibility)
05

Safety considerations

None specifically for DPYD-AS2. Possible concerns are theoretical, related to off-target or unintended modulation of DPYD leading to drug toxicity
06

Interacting drugs

None directly. Indirectly related to fluoropyrimidine drugs (fluorouracil, capecitabine, tegafur) and gemcitabine via regulation of DPYD
07

Biomarkers

DPYD-AS2 itself is not used as a biomarker; DPYD gene variants and expression levels are established biomarkers for fluoropyrimidine toxicity

Beyond the preview

Go deeper on DPYD antisense RNA 2 (non-protein coding) (DPYD-AS2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPYD antisense RNA 2 (non-protein coding) (DPYD-AS2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call